United States Needle Free Injections Market Outlook to 2023 - Product Image

United States Needle Free Injections Market Outlook to 2023

  • ID: 4334375
  • Report
  • Region: United States
  • 82 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Antares Pharma Inc
  • INJEX - Equidyne Systems
  • MK Global Co.
  • PharmaJet Inc
  • MORE
United States Needle Free Injections Market Outlook to 2023

Summary

The new report, "United States Needle Free Injections Market Outlook to 2023", provides key market data on the United States Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Needle Free Injections.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope
  • Market size and company share data for Needle Free Injections.
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the United States Needle Free Injections market.
  • Key players covered include INJEX - Equidyne Systems, Bioject Medical Technologies Inc and Antares Pharma Inc.
Reasons to Buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Antares Pharma Inc
  • INJEX - Equidyne Systems
  • MK Global Co.
  • PharmaJet Inc
  • MORE
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Introduction
2.1 What Is This Report About?
2.2 Needle Free Injections Market Segmentation
2.3 Definitions of Markets Covered in the Report
3. Needle Free Injections Market, United States
3.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016
3.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023
3.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016
3.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023
3.5 Needle Free Injections Market, United States, Average Price ($), 2009-2023
3.6 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016
3.7 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016
4. Overview of Key Companies in United States, Needle Free Injections Market
4.1 INJEX - Equidyne Systems
4.1.1 Company Overview
4.2 Bioject Medical Technologies Inc
4.2.1 Company Overview
4.3 Antares Pharma Inc
4.3.1 Company Overview
4.4 PharmaJet Inc
4.4.1 Company Overview
4.5 MK Global Co.
4.5.1 Company Overview
5. Needle Free Injections Market Pipeline Products
6. Financial Deals Landscape
6.1 Debt Offerings
6.1.1 Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036
6.1.2 Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024
6.2 Equity Offerings
6.2.1 Valeritas Files Registration Statement for IPO for up to USD50 Million
6.3 Partnerships
6.3.1 PharmaJet Enters into Agreement with Serum Institute of India
6.4 Venture Financing
6.4.1 Pharmajet Raises USD3 Million in Venture Financing
6.4.2 Enable Injections Raises USD30 Million in Series A Financing
6.4.3 QuiO Technologies Raises USD1.05 Million in Seed Financing
6.4.4 Enable Injections Raises USD10 Million in Venture Financing
7. Recent Developments
7.1 Corporate Communications
7.1.1 Jun 06, 2017: Valeritas Appoints Peter J. Devlin to Chairman of its Board of Directors
7.1.2 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
7.1.3 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
7.1.4 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board
7.1.5 Jan 05, 2017: Zogenix Announces CFO Transition
7.1.6 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors
7.1.7 Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology
7.1.8 Nov 15, 2016: Oncoceutics Presents Abstracts on ONC201 at 2016 American Society of Hematology Meeting
7.1.9 Nov 14, 2016: Olympus VISERA 4K UHD Receives Excellence in Surgical Products Awards, Minimally Invasive Surgical Product Category
7.1.10 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
7.1.11 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
7.1.12 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors
7.1.13 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer
7.1.14 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
7.1.15 Jul 13, 2016: Valeritas Appoints Brian K. Roberts to its Board of Directors
7.2 Financial Announcements
7.2.1 May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results
7.2.2 May 12, 2017: Valeritas Reports First Quarter 2017 Financial Results
7.2.3 May 10, 2017: ICU Medical Announces First Quarter 2017 Results
7.2.4 May 09, 2017: Antares Pharma Reports First Quarter 2017 Operating and Financial Results
7.2.5 May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results
7.2.6 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results
7.2.7 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017
7.2.8 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017
7.2.9 Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
7.2.10 Mar 14, 2017: Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results
7.2.11 Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
7.2.12 Mar 01, 2017: ICU Medical Announces Fourth Quarter and Fiscal Year 2016 Results
7.2.13 Feb 21, 2017: Valeritas Reports Fourth Quarter and Full Year 2016 Financial Results
7.2.14 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
7.2.15 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
7.2.16 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results
7.2.17 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results
7.2.18 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results
7.2.19 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results
7.2.20 Nov 09, 2016: ICU Medical Announces Third Quarter 2016 Results
7.2.21 Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results
7.2.22 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
7.2.23 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016
7.2.24 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results
7.2.25 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results
7.2.26 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results
7.2.27 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results
7.2.28 Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
7.2.29 Aug 08, 2016: ICU Medical Announces Second Quarter 2016 Results
7.2.30 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
7.2.31 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016
7.3 Government and Public Interest
7.3.1 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal
7.3.2 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy
7.4 Legal And Regulatory
7.4.1 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges
7.4.2 Nov 17, 2016: New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant
7.5 Other Significant Developments
7.5.1 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
7.5.2 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration
7.5.3 Jul 15, 2016: PhRMA Welcomes Five New Member Companies
8. Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Company Share Analysis
8.1.5 Distribution Share Analysis
8.1.6 Benchmarking
8.2 Consulting
8.3 Contact Us
8.4 Disclaimer

1.1 List of Tables
Table 1: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
Table 2: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
Table 3: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016
Table 4: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023
Table 5: Needle Free Injections Market, United States, Average Price ($), Historic, 2009-2016
Table 6: Needle Free Injections Market, United States, Average Price ($), Forecast, 2016-2023
Table 7: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016
Table 8: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016
Table 9: Needle Free Injections Market Pipeline Products
Table 10: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036
Table 11: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024
Table 12: Valeritas Files Registration Statement for IPO for up to USD50 Million
Table 13: PharmaJet Enters into Agreement with Serum Institute of India
Table 14: Pharmajet Raises USD3 Million in Venture Financing
Table 15: Enable Injections Raises USD30 Million in Series A Financing
Table 16: QuiO Technologies Raises USD1.05 Million in Seed Financing
Table 17: Enable Injections Raises USD10 Million in Venture Financing

1.2 List of Figures
Figure 1: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
Figure 2: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
Figure 3: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016
Figure 4: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023
Figure 5: Needle Free Injections Market, United States, Company Share (%) 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • INJEX - Equidyne Systems
  • Bioject Medical Technologies Inc
  • Antares Pharma Inc
  • PharmaJet Inc
  • MK Global Co.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll